Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Liraglutide and Liver Injury: Rare Case Report with Literature Review.

Salehi AM, Hasanzarrini M, Salehi H, Jenabi E

Endocrine, metabolic & immune disorders drug targets1 Jan 2024Cited by 4 (Europe PMC)

PMID37885115 (opens in a new tab)DOI10.2174/0118715303180615231011053011 (opens in a new tab)PepBankPUB-37885115
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 41-year-old woman with type 2 diabetes, liver tests showed hepatocellular injury that was suspected to be drug-induced liver injury from liraglutide.

    In plain wordsIn one woman with type 2 diabetes, liver tests showed liver injury that doctors suspected was caused by liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseDrug-induced liver injury
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Her liver functional test (LFT) was consistent with hepatocellular injury; however, laboratory tests and abdominal ultrasound were used to rule out autoimmune hepatitis.
    2 context sentences
    Summary · context
    Due to concerns for drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl cysteine was prescribed.
    Summary · context
    The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan.
  2. 02HumanCase report or seriesSafety outcome

    After liraglutide was stopped and N-acetyl cysteine was prescribed, the patient's liver tests decreased and liver enzymes returned to normal after 2 months.

    In plain wordsIn this one woman, liver enzymes returned to normal after liraglutide was stopped and N-acetyl cysteine was given.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver enzyme levels after liraglutide discontinuation
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the fifth day of hospitalization, the patient's symptoms resolved and his LFT started to decrease on the sixth day after 2 months, the patient's liver enzyme levels returned to normal
    1 context sentence
    Summary · context
    The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.